Reliable data on large cohorts of patients with glioblas- toma are needed because such studies differ importantly from trials that have a strong bias toward the recruit- ment of younger patients with a higher performance sta- tus. We analyzed the outcome of 676 patients with histo- logically confirmed newly diagnosed glioblastoma who were treated consecutively at a single institution over a 7-year period (1997 - 2003) with follow-up to April 30, 2006. Survival probabilities were 57% at 1 year, 16% at 2 years, and 7% at 3 years. Progression-free survival was 15% at 1 year. Prolongation of survival was signifi - cantly associated with surgery in patients with a good performance status, whatever the patient's age, with an adjusted hazard ratio of 0.55 (p , 0.001) or a 45% relative decrease in the risk of death. Radiotherapy and Prognostic factors for survival in 676 consecutive patients with newly diagnosed primary glioblastoma chemotherapy improved survival, with adjusted hazard ratios of 0.61 (p 5 0.001) and 0.89 (p 5 0.04), respec- tively, regardless of age, performance status, or residual tumor volume. Recurrence occurred in 99% of patients throughout the follow-up. Reoperation was performed in one-fourth of these patients but was not effective, whether performed within 9 months (hazard ratio, 0.86; p 5 0.256) or after 9 months (hazard ratio, 0.98; p 5 0.860) of initial surgery, whereas second-line che-